Atea Pharmaceuticals (AVIR) vs YD Bio (YDES)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed YD Bio (YDES) over the past year, gaining 66.3% versus a loss of 66.1%. YD Bio is the larger company by market cap ($478.5 million vs $412.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | YDES |
|---|---|---|
| Share price | $5.14 | $6.76 |
| Market cap | $412.25M | $478.47M |
| 1-day change | -0.29% | +16.67% |
| YTD return | +44.40% | -52.50% |
| 1-year return | +66.29% | -66.06% |
| 5-year return | -86.88% | — |
| EPS (TTM) | $-2.09 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.45 | $22.00 |
| 52-week low | $2.87 | $1.70 |
| Distance from 52-week high | -20.31% | -69.30% |
| Analyst consensus | none | — |
| Avg. price target upside | +83.27% | — |
| Average volume | 298.98K | 284.92K |
| Shares outstanding | 80.20M | 70.83M |
| Employees | 55 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVIR has outperformed YDES by 132.4 percentage points over the past year.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About YD Bio
YDES stock →YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma.
Health Care · Medical Specialities · 13 employees
AVIR vs YDES FAQ
Which is bigger, Atea Pharmaceuticals or YD Bio?
YD Bio (YDES) is larger, with a market capitalization of $478.47M compared with $412.25M for Atea Pharmaceuticals (AVIR).
Which stock has performed better over the past year, AVIR or YDES?
AVIR returned +66.29% over the past 12 months, compared with -66.06% for YDES (price return, excluding dividends). Past performance does not predict future results.
Are Atea Pharmaceuticals and YD Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Atea Pharmaceuticals and Medical Specialities for YD Bio.